ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Assessment of Registered Clinical Trial Designs: Comparison of L-Arginine and/or L-Citrulline Interventions for Hypertension.

登録臨床試験デザインの評価:高血圧に対するL-アルギニンおよび/またはL-シトルリン介入の比較 (機械翻訳の邦題)

Pharmaceuticals (Basel, Switzerland)2024Hillsley AB, McLachlan CS
研究デザインその他の原著論文
対象未確定

記録の確認項目

研究デザイン
その他の原著論文
対象
未確定
出版年
2024
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/03
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

本研究は、高血圧に対するL-アルギニンおよびL-シトルリン介入の慢性血圧低下効果を検証した臨床試験のデザインを評価した。clinicaltrials.govで「完了」「成人」「血圧低下を主要評価項目」等の条件で検索し、44件の完了試験のうち5件を分析対象とした。その結果、参加者基準(サンプルサイズ、年齢、性別)、介入デザイン(用量、期間)、主要評価項目(収縮期・拡張期血圧の変化)に不均一性が認められた。結論として、現在のランダム化比較試験では、一般集団におけるL-アルギニンまたはL-シトルリンの血管内皮反応性への正の効果や慢性的な血圧低下効果を示す頑健なエビデンスは不足しており、メタ分析の不均一性は試験デザインの差異に起因する可能性が示唆された。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Background: L-Arginine (Arg) is an essential amino acid and a precursor for the synthesis of vascular nitric oxide, while L-Citrulline is a non-essential amino acid substrate for increasing L-arginine. Both L-arginine and L-Citrulline in translational studies may acutely lower the blood pressure. Current meta-analysis for L-arginine or L-Citrulline interventions in blood pressure have identified significant heterogeneity. Clinical trial evidence for L-arginine or L-Citrulline in chronic blood pressure reduction in the general population requires an examination of trial designs, as not all translational studies may have influenced vascular reactivity. Our aims are to explore whether L-arginine and L-citrulline intervention trials in chronic blood pressure consider standardized end points relevant to the general adult populations.Methods: A step-wise search on clinicaltrials.gov, the U.S. Library of Medicine registry for clinical trials, was performed including the following keyword search parameters: "completed" "L-Citrulline" "L-arginine" trial", and "adults", involving "blood pressure" reduction as a primary end point in adult humans.Results: Of the forty-four completed trials, only five were included for analysis. Following the careful evaluation of trial design, we observed heterogeneity across participant inclusion criteria (population sample size, age range, sex), interventional design (dosages, duration), and primary outcomes, measured with respect to changes in diastolic or systolic blood pressure.Conclusion: In conclusion, there is a lack of robust trial design evidence to suggest that L-arginine or L-Citrulline, based on current RCTs in the general population, have an overall positive effect on vascular endothelial reactivity and a beneficial chronic blood pressure-lowering effect. Indeed, conclusions drawn from human meta-analysis studies have been heterogenous between studies, which may be attributed to study design heterogeneity, including differences in sample population, age, and blood pressure at the time of entry. Inconsistencies in the study design poses a challenge for systematic reviews and meta-analysis to accurately assess the effect size and impact of L-arginine or L-citrulline on both systolic and diastolic blood pressure.

DOI 10.3390/ph17040477

PMID 38675437

原文・出典を見る →